Last Updated on October 10, 2024 by The Health Master
An expert panel of India’s central drug authority has recommended permission for conducting a phase-3 clinical trial of C-19 vaccine Covovax as a booster dose in adults, official sources said on Sunday.
The Drugs Controller General of India (DCGI) has already approved Covovax for restricted use in emergency situations in adults on December 28.
It is yet to be included in the country’s inoculation programme.
The Subject Expert Committee on C-19 of the Central Drugs Standard Control Organisation had on Friday recommended giving permission for conducting a phase-3 clinical trial of the single-dose C-19 vaccine Sputnik Light as a booster dose.
In February, Director, Government and Regulatory Affairs at Serum Institute of India, Prakash Kumar Singh had sought from DCGI nod to conduct a phase-3, observer-blind, randomized, controlled study to evaluate the safety and immunogenicity of Covovax as a booster dose in adults who were vaccinated with Covishield or Covaxin at least 3 months ago, an official source had said.
Singh had stated many countries have already started administering booster doses to their citizens considering the uncertainties of the C-19 pandemic.
“We are sure that your approval for conducting this clinical trial will ensure early availability of Covovax for booster dose use for people of our country as well as the world at large in line with our prime minister’s vision of ‘Making in India for the World’.
“Our firm is committed to providing world-class life-saving vaccines at an affordable price under the visionary leadership of our CEO Adar C Poonawalla. We request you to kindly grant us permission to conduct a phase-3 clinical trial for booster dose of Covovax in Indian adults,” Singh is learnt to have stated in the application.
Covovax is manufactured by technology transfer from Novavax. It has been approved by the European Medicines Agency for conditional marketing authorisation and has also been granted emergency use listing by WHO.
In August 2020, the US-based vaccine maker Novavax Inc had announced a licence agreement with Serum Institute of India for the development and commercialisation of NVX-CoV2373, its C-19 vaccine candidate, in low and middle-income countries and India.
Notifications: New Drugs, FDC, Clinical Trial
Other details about New Drugs, FDCs, Clinical trial
Clarification sought from CDSCO on approval status of Clotrimazole 1% mouth paint
Govt recommends imposition of anti-dumping duty on import of Dicyclohexylcarbodiimide from China
USFDA approves expanded use of cancer drug Opdivo
Govt releases draft Unani Pharmacopoeia of India
USFDA declines pediatric EUA for vaccine Covaxin
NPPA cancels study access of medicine at affordable prices
WHO updates its treatment guidelines to include Molnupiravir
USFDA gives nod to Lupin for generic Jublia topical solution
Govt listed 213 drugs for which procurement agencies could not find local manufacturers
Latest Notifications regarding Pharmaceuticals
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
